ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) — ALTARGOPMS

Skin Infections, Bacterial Clinical Trial

Official title:
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information

Status Completed

Clinical Trial Summary

This is an open label, multi-centre, non-interventional post-marketing surveillance.

Clinical Trial Description

This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of ALTARGO(retapamulin) treated in Korean patients according to the prescribing information.

ALTARGO is a trademark of the GlaxoSmithKline group of companies. ;

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01445600
Study type	Observational
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	N/A
Start date	November 2012
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00555061` - Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.	Phase 4
Completed	`NCT00684177` - Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)	Phase 3
Completed	`NCT01153880` - United States Pharmacovigilence Retapamulin-Prescribing	N/A
Completed	`NCT01209078` - GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection	Phase 2
Completed	`NCT00852540` - Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA	Phase 3
Completed	`NCT00133874` - Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo	Phase 3
Completed	`NCT01812382` - Retapamulin Microdialysis Feasibility Study	Phase 1